Cartesian maps the path for an autoimmune disease cell therapy

[cafead]

via Now Cartesian Therapeutics, a private, Maryland-based biotech, reckons it has cracked the problem by using mRNA to generate Car-T cells, a procedure not dependent on cell engraftment and thus not requiring lymphodepletion. Even better, its myasthenia gravis trial, just published in Lancet Neurology, has shown impressive efficacy in most patients.

article source